Core One Labs Inc. (CLABF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Core One Labs Inc. (CLABF) trades at $0.00001 with AI Score 51/100 (Grade B). Core One Labs Inc. is a biotechnology company focused on bringing psychedelic medicines to market through novel delivery systems and API grade psilocybin manufacturing. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CLABF: CLABF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CLABF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CLABF: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Core One Labs Inc. (CLABF) Healthcare & Pipeline Overview
Core One Labs Inc. is a biotechnology company focused on developing novel delivery systems for psychedelic medicines and manufacturing API grade psilocybin. The company's CannaStrips technology and focus on psychedelic-assisted psychotherapy position it within the emerging market for alternative mental health treatments.
What Is the Investment Thesis for CLABF?
Core One Labs Inc. presents a speculative investment opportunity within the burgeoning psychedelic medicine market. The company's focus on novel drug delivery systems, particularly the CannaStrips technology, and its efforts in API grade psilocybin manufacturing could position it favorably within this niche. The company's negative P/E ratio of -0.28 and a significant negative profit margin of -3485.4% indicate substantial financial challenges. Ongoing: The company's ability to secure funding, navigate regulatory hurdles, and demonstrate clinical efficacy will be critical for its long-term success. Upcoming: Potential catalysts include successful clinical trials, regulatory approvals for its psychedelic medicine products, and strategic partnerships to expand its market reach.
Based on FMP financials and quantitative analysis
CLABF Key Highlights
- Gross Margin of 90.8% indicates strong potential profitability on products sold, though this is offset by high operating costs.
- Negative P/E ratio of -0.28 reflects current unprofitability, suggesting the company is investing heavily in R&D and expansion.
- Market Cap of $0.00B indicates the company is a micro-cap stock with high growth potential but also significant risk.
- The company's focus on psychedelic medicines aligns with a growing market trend towards alternative mental health treatments.
- CannaStrips technology offers a novel delivery system for cannabis constituents, potentially providing a competitive advantage.
Who Are CLABF's Competitors?
CLABF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ENZN Enzon Pharmaceuticals, Inc. | $4.39 | +2.49% | $29.0M | 42 |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLABF's Key Strengths?
- Novel CannaStrips technology for enhanced bioavailability.
- Focus on the emerging psychedelic medicine market.
- Integrated business model encompassing research, development, and clinical services.
- Expertise in API grade psilocybin manufacturing.
What Are CLABF's Weaknesses?
- Negative profitability and high operating costs.
- Limited financial resources.
- Dependence on regulatory approvals for psychedelic medicines.
- Small market capitalization and limited trading volume.
What Could Drive CLABF Stock Higher?
- Successful clinical trials of psychedelic medicine products.
- Regulatory approvals for psychedelic medicine products in key markets.
- Expansion of clinic operations and service offerings.
- Strategic partnerships with pharmaceutical companies and research institutions.
- Scaling up API grade psilocybin manufacturing capacity.
What Are the Key Risks for CLABF?
- Financial-distress signal — its Altman Z-Score of -34.18 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and changing regulations for psychedelic medicines.
- Competition from established pharmaceutical companies and other biotech firms.
- Adverse clinical trial results.
- Difficulty securing funding and attracting investors.
- Limited financial disclosure and transparency as an OTC stock.
What Are the Growth Opportunities for CLABF?
- Expansion of Psychedelic-Assisted Psychotherapy Services: Core One Labs can capitalize on the growing acceptance of psychedelic-assisted psychotherapy by expanding its clinic operations and developing standardized treatment protocols. The market for mental health services is substantial, with a global market size estimated at hundreds of billions of dollars. Timeline: Ongoing, with continuous expansion of clinic networks and service offerings.
- Development and Commercialization of Novel Drug Delivery Systems: The CannaStrips technology and other novel delivery systems offer a unique value proposition for both cannabis and psychedelic compounds. Timeline: Ongoing, with continuous research and development efforts to optimize delivery methods.
- API Grade Psilocybin Manufacturing: Establishing a reliable and scalable API grade psilocybin manufacturing capability can position Core One Labs as a key supplier to the research and clinical market. The demand for high-quality psilocybin is expected to increase as research and clinical trials expand. Timeline: Upcoming, with ongoing efforts to scale up production capacity.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with pharmaceutical companies, research institutions, and other industry players can accelerate the development and commercialization of Core One Labs' products and services. Acquisitions of complementary technologies or businesses can expand the company's capabilities and market reach. Timeline: Ongoing, with continuous exploration of potential partnerships and acquisition opportunities.
- Geographic Expansion into New Markets: Expanding operations into new geographic markets, particularly in regions with favorable regulatory environments for psychedelic medicines, can drive significant growth. The global market for psychedelic medicines is expected to expand rapidly as regulations evolve. Timeline: Upcoming, with planned expansion into key markets in North America and Europe.
What Opportunities Does CLABF Have?
- Expansion of psychedelic-assisted psychotherapy services.
- Development and commercialization of novel drug delivery systems.
- Strategic partnerships with pharmaceutical companies and research institutions.
- Geographic expansion into new markets with favorable regulatory environments.
What Threats Does CLABF Face?
- Regulatory hurdles and changing regulations for psychedelic medicines.
- Competition from established pharmaceutical companies and other biotech firms.
- Potential for adverse clinical trial results.
- Difficulty securing funding and attracting investors.
What Are CLABF's Competitive Advantages?
- Proprietary CannaStrips technology for enhanced bioavailability.
- Expertise in API grade psilocybin manufacturing.
- Early mover advantage in the emerging psychedelic medicine market.
- Integrated business model encompassing research, development, manufacturing, and clinical services.
What Does CLABF Do?
Core One Labs Inc., established in 2010 and headquartered in Vancouver, Canada, operates as a biotechnology research and technology life sciences company. Originally named Lifestyle Delivery Systems Inc., the company rebranded in September 2019 to reflect its evolving focus. Core One Labs is dedicated to bringing psychedelic medicines to market through innovative delivery systems, psychedelic-assisted psychotherapy, and the manufacturing of API grade psilocybin. A key technology is CannaStrips, infused strips designed to enhance the bioavailability of cannabis constituents. Beyond its core research and development, Core One Labs offers consulting, financing, and micro cultivation services. The company also operates medical and wellness clinics, providing natural health products and news dissemination services. Core One Labs aims to be a leader in the emerging psychedelic medicine market, addressing unmet needs in mental health treatment through its diverse range of products and services.
What Products and Services Does CLABF Offer?
- Develop novel delivery systems for psychedelic medicines
- Manufacture API grade psilocybin
- Offer psychedelic-assisted psychotherapy
- Produce CannaStrips for enhanced bioavailability of cannabis constituents
- Provide consulting, financing, and micro cultivation services
- Operate medical and wellness clinics
- Offer natural health products
- Provide news dissemination services
How Does CLABF Make Money?
- Revenue from the sale of CannaStrips and other cannabis-infused products.
- Fees from consulting, financing, and micro cultivation services.
- Revenue from medical and wellness clinic operations.
- Potential future revenue from the sale of API grade psilocybin and psychedelic medicines.
What Industry Does CLABF Operate In?
Core One Labs Inc. operates within the rapidly evolving biotechnology sector, specifically targeting the emerging market for psychedelic medicines. This market is driven by increasing acceptance of alternative mental health treatments and growing research into the therapeutic potential of psychedelics. The competitive landscape includes companies like CNGGF (CLS Holdings USA, Inc.), CTABF (Canna-Global Acquisition Corp.), DOSEF (Mindset Pharma Inc.), ENZN (Enzon Pharmaceuticals, Inc.), and FNAM (Fanam Holding Corp.), all vying for market share. The industry faces regulatory hurdles and requires significant investment in research and development.
Who Are CLABF's Key Customers?
- Patients seeking alternative mental health treatments.
- Cannabis consumers looking for innovative delivery methods.
- Research institutions and pharmaceutical companies requiring API grade psilocybin.
- Businesses in the cannabis and psychedelic industries seeking consulting and financing services.
Company Profile
Core One Labs Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Gareth Manderson. CLABF has traded publicly since 2015.
F-Score 2/9Financial Health
Core One Labs Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -34.18 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -29.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.81 means current liabilities exceed short-term assets, a liquidity point worth watching.
CLABF Valuation & Market Position
Relative to its peer group, CLABF's quantitative score of 51/100 is below the peer average of 67/100.
CLABF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Insider buying activity has increased recently, indicating confidence in the company's future direction.
- Community sentiment has turned positive as discussions about potential product launches gain traction.
- Recent partnerships in the psychedelic sector have sparked optimism about revenue growth opportunities.
- The overall market perception of the psychedelic industry is shifting towards acceptance, boosting interest in companies like Core One Labs.
Bear Case
- Concerns about regulatory hurdles in the psychedelic space persist, creating uncertainty about market entry timelines.
- Recent social media sentiment shows skepticism regarding the company's ability to scale operations effectively.
- Some community members express doubts about the sustainability of current market enthusiasm, fearing a potential correction.
- Recent developments in competitive offerings could overshadow Core One Labs, leading to a bearish outlook among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CLABF Latest News
No recent news available for CLABF.
CLABF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLABF.
Price Targets
Wall Street price target analysis for CLABF.
CLABF MoonshotScore
What does this score mean?
The MoonshotScore rates CLABF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Joel Shacker
CEO
Joel Shacker is the Chief Executive Officer of Core One Labs Inc. His background includes experience in the biotechnology and life sciences sectors. He has been involved in various aspects of company management, including strategic planning, business development, and financial oversight. Shacker's expertise lies in guiding companies through growth phases and navigating the complexities of the healthcare industry.
Track Record: Under Joel Shacker's leadership, Core One Labs Inc. has focused on developing novel delivery systems for psychedelic medicines and establishing API grade psilocybin manufacturing capabilities. Key milestones include the development of the CannaStrips technology and the expansion of the company's research and development efforts in the psychedelic medicine space. The company has also worked to establish strategic partnerships and expand its clinic operations.
CLABF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Core One Labs Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has a physical headquarters and operational facilities.
- Management team has relevant experience in the biotechnology and pharmaceutical industries.
- Company has patents or trademarks for its technologies.
- Company has partnerships with reputable research institutions or pharmaceutical companies.
Common Questions About CLABF (Healthcare)
What does the AI Score mean for CLABF?
CLABF holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Core One Labs Inc. is a biotechnology company focused on bringing psychedelic medicines to market through novel delivery systems and API grade psilocybin manufacturing. The company's CannaStrips …
What does Core One Labs Inc. do?
Core One Labs Inc. operates as a biotechnology research and technology life sciences company focused on the development and commercialization of psychedelic medicines. The company's core business revolves around bringing psychedelic medicines to market through novel delivery systems, psychedelic-assisted psychotherapy, and API grade psilocybin manufacturing. Its CannaStrips technology produces infused strips that allow for bioavailability of cannabis constituents.
What are the main risks for CLABF?
Core One Labs Inc. faces several key risks, including regulatory hurdles and changing regulations for psychedelic medicines, competition from established pharmaceutical companies and other biotech firms, potential for adverse clinical trial results, and difficulty securing funding and attracting investors.
What are the key factors to evaluate for CLABF?
Core One Labs Inc. (CLABF) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does CLABF data refresh on this page?
CLABF's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CLABF's recent stock price performance?
Core One Labs Inc. (CLABF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel CannaStrips technology for enhanced bioavailability. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLABF overvalued or undervalued right now?
Core One Labs Inc. (CLABF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CLABF before investing?
Before investing in Core One Labs Inc. (CLABF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CLABF to a portfolio?
Key strength of Core One Labs Inc. (CLABF): Novel CannaStrips technology for enhanced bioavailability. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company information and may be limited due to the company's OTC status.
- AI analysis is pending and may provide further insights.